QS-21
Based on 1 Customer Validation
QS-21 is a mixture of QS-21-Xyl (HY-101092B) and QS-21-Api (HY-101092), with a ratio of 35:65. QS-21 is an innate immune system-targeted adjuvant. QS-21 is promising for research of oncology vaccines (e.g., melanoma) and infectious disease vaccines (e.g., HIV, malaria).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.10%
- Formule: C92H148O46
- Masse moléculaire:1990.14
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Chemical Information
-
Appearance Solid
-
Masse moléculaire 1990.14
-
Formule C92H148O46
-
Color White to off-white
-
SMILES
O[C@H]1COC[C@@H](O)[C@@H]1O.O[C@H]2COC[C@]2(O)CO.O[C@H]([C@@H]([C@H]([C@@H](O3)C)O[C@H]4[C@@H]([C@H]([C@@H](CO4)O)O[R])O)O)[C@@H]3O[C@H]([C@H]([C@H]([C@H](O5)C)OC(C[C@@H](O)C[C@H](OC(C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@@H]6O[C@H]([C@@H]([C@H]6O)O)CO)=O)[C@H](CC)C)=O)O)[C@@H]5OC([C@]78[C@](CC(C)(CC8)C)([H])C9=CC[C@@]([C@@]%10([C@@]([C@@](C)([C@H](CC%10)O[C@H]%11[C@@H]([C@H]([C@@H]([C@H](O%11)C(O)=O)O)O[C@H]%12[C@@H]([C@H]([C@@H](CO%12)O)O)O)O[C@@H]%13O[C@@H]([C@@H]([C@@H]([C@H]%13O)O)O)CO)C=O)([H])CC%14)C)([H])[C@]%14(C)[C@@]9(C[C@H]7O)C)=O.[35%].[65%]
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
-
Fiche technique (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
QS-21 Related Classifications
HY-101092A Related Classifications
Powered by Bioz